Safety of intrathecal treatment with nusinersen therapy with SMA

Safety of intrathecal treatment with nusinersen therapy with spinal muscular atrophy SMA Typ 2/3 New study from University Essen shows great results University Essen treated a total of 28 adult SMA patients (9 patients with SMA type 2 and 19 patients with SMA type 3) aged between 18–61 years with nusinersen…. Att fortsätt läsa